Intangible Assets

3 Months Ended

Mar. 31, 2026

Goodwill and Intangible Assets Disclosure [Abstract]

Note 13. Intangible Assets

EryDel Intangible Assets

The following table provides details of the carrying amount of the Company's indefinite-lived intangible asset (in thousands):


		(in thousands)
In-process research and development:
	Balance as of December 31, 2025	$	67,361
	Impairment charges		(67,361	)
	Balance as of March 31, 2026	$	—

The following table provides details of the carrying amount of the Company's finite-lived intangible asset (in thousands, except useful life):


			As of March 31, 2026								As of December 31, 2025
		Useful life	Cost		Accumulated Amortization			Net Carrying Value			Cost		Accumulated Amortization			Net Carrying Value
Finite life intangible assets:
	Trade name	21 years	$	460		(49	)	$	411		$	460		(26	)	$	434
	Foreign currency translation adjustments								36								(8	)
	Impairment charges								(447	)							—
	Total							$	—							$	426

In January 2026, the Company ceased clinical development of eDSP as the primary and secondary endpoints did not achieve statistical significance in its Phase 3 NEAT clinical trial (See Note 1). As a result, several of the assumptions used in determining the initial fair value have changed including expected cash flows and thus triggered the need for an interim impairment assessment as required under ASC 350. As a result, the fair value was determined to be significantly below its carrying value and the Company recognized a total impairment charge of $67.8 million for for indefinite and finite-lived intangible assets the three months ended March 31, 2026.

Quince Therapeutics, Inc. 10-Q